Contrasting Nemaura Medical (NASDAQ:NMRD) & PAVmed (NASDAQ:PAVM)

Nemaura Medical (NASDAQ:NMRD) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Volatility & Risk

Nemaura Medical has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 41.6% of Nemaura Medical shares are owned by insiders. Comparatively, 12.6% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Nemaura Medical and PAVmed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	1	0	3.00
PAVmed	0	1	0	0	2.00

Nemaura Medical currently has a consensus target price of $2.50, suggesting a potential upside of 5,713.28%. PAVmed has a consensus target price of $21.00, suggesting a potential upside of 914.49%. Given Nemaura Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Nemaura Medical is more favorable than PAVmed.

Profitability

This table compares Nemaura Medical and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	-142.69%
PAVmed	-2,617.25%	N/A	-85.99%

Earnings and Valuation

This table compares Nemaura Medical and PAVmed’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$80,000.00	21.69	-$14.14 million	($0.39)	-0.11
PAVmed	$2.45 million	7.97	-$64.18 million	($9.33)	-0.22

Nemaura Medical has higher earnings, but lower revenue than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Nemaura Medical beats PAVmed on 8 of the 12 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About PAVmed

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.